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Current diagnostic standards involve severe acute respiratory syndrome cor-
onavirus 2 (SARS‐CoV‐2) detection in nasopharyngeal swabs (NPS), but saliva is an
attractive and noninvasive option for diagnosis. The objectives were to determine
the performance of saliva in comparison with NPS for detecting SARS‐CoV‐2 and to
compare the optimized home brew reverse‐transcription polymerase chain reaction
(RT‐PCR) with a commercial RT‐PCR. Paired NPS and saliva specimens were pro-
spectively collected and tested by RT‐PCR from patients presenting at an emer-
gency room with signs and symptoms compatible with coronavirus disease‐2019. A
total of 348 samples from 174 patients were tested by RT‐PCR assays. Among
174 patients with symptoms, 63 (36%) were SARS‐CoV‐2 positive in NPS using the
optimized home‐brew PCR. Of these 63 patients, 61 (98%) were also positive in
saliva. An additional positive SARS‐CoV‐2 saliva was detected in a patient with
pneumonia. Kappa Cohen's coefficient agreement between NPS and saliva was 0.96
(95% confidence interval [CI], 0.90–0.99). Median Ct values in NPS versus saliva
were 18.88 (interquartile range [IQR], 15.60–23.58; range, 11.97–38.10) versus
26.10 (IQR, 22.75–30.06; range, 13.78–39.22), respectively (p < .0001). The opti-
mized home‐brew RT‐PCR demonstrated higher analytical and clinical sensitivity
compared with the commercial RT‐PCR assay. A high sensitivity (98%) and agree-
ment (kappa 0.96) in saliva samples compared to NPS was demonstrated when using
an optimized home‐brew PCR even when the viral load in saliva was lower than in
NPS. This noninvasive sample is easy to collect, requires less consumable and avoids
discomfort to patients. Importantly, self‐collection of saliva can diminish exposure to
healthcare personnel.
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1 | INTRODUCTION
The number of patients infected with severe acute respiratory syn-
drome coronavirus 2 (SARS‐CoV‐2) causing coronavirus disease‐
2019 (COVID‐19) remains increasing during the ongoing pandemic.
A crucial strategy for controlling transmission relies on expanding
diagnosis. The current diagnostic standard involves detection of
SARS‐CoV‐2 by reverse‐transcription polymerase chain reaction
(RT‐PCR) using nasopharyngeal swabs (NPS). However, NPS are
associated with patient's discomfort or complications—such as
iatrogenic cerebrospinal fluid leak—as well as an increasing health-
care worker's exposure to SARS‐CoV‐2.1,2
Saliva is an attractive and noninvasive option for diagnosing
SARS‐CoV‐2 and sampling enables self‐collection without causing
discomfort or pain. In addition, self‐collection of saliva can reduce
the exposure to healthcare personnel by avoiding cough, sneezing,
and/or aerosolization during sampling. Furthermore, saliva testing
requires less consumables, offering a significant benefit when there
is shortage of supplies.3
The value of using saliva for SARS‐CoV‐2 detection has been
variable between different studies. Such variability may be related to
the type of collection, processing, detection techniques, and/or PCR
assays.4
The objectives of this study were to determine the performance
of saliva in comparison to NPS for detecting SARS‐CoV‐2 and to
compare our optimized home brew RT‐PCR with a commercial
RT‐PCR.
2 | MATERIALS AND METHODS
Paired NPS and saliva were prospectively collected from patients
presenting at the emergency room (ER) in CEMIC University
Hospital from August to September 2020. Patients more than or
equal to 18 years old with signs or symptoms potentially due to
COVID‐19 were invited to participate in the study. This study was
approved by the Ethics Committee of CEMIC (Protocol: 1298/20).
Signs or symptoms of COVID‐19 included fever (>37.5°C),
throat, abdominal or chest pain, rhinorrhea, cough, dyspnea, myal-
gias, headache, anosmia, or dysgeusia. All patients were evaluated by
a trained ER physician.
NPS were obtained and placed in a sterile tube with 2 ml viral
transport media (Minimun Essential Medium; Gibco); L‐Glutamine
200 mM; HEPES 1 N; Bovine Albumin 5%; Sigma; Sodium
Bicarbonate 7.5%; Penicillin, Streptomycin, and Amphotericin;
pH = 7.2). Patients were also instructed to collect saliva by
themselves in a plastic sterile container without any transport
media. Both NPS and saliva samples were transported at room
temperature to the laboratory within 2 h of sample collection.
NPS collected in 2 ml of viral transport medium were vortexed in
a biosafety cabinet and an aliquot was used for nucleic acid ex-
traction. Saliva samples were conserved at 4°C until processed in
a biosafety cabinet within 48 h from arrival. Viscous saliva
samples were mechanically disrupted by adding 500 µl viral
transport medium.
Nucleic acid was extracted from 100 µl and eluted in 15 µl using
manual columns (Quick‐RNA™ Viral Kit, Zymo Research Corp.) fol-
lowing manufacturer's recommendation. An in‐house one‐step real‐
time RT‐PCR assay targeting the E gene of SARS‐CoV‐2 was per-
formed.5 Optimization of this assay was done to achieve a higher
analytical sensitivity. Specifically, magnesium final concentration was
increased to 3.8mM and cycling conditions were modified into three
PCR steps. Such steps included an initial transcription stage (10min
at 55°C), followed by 2min at 95°C, and subsequently by 45 cycles
(95°C for 15 s, 55°C for 30 s, and 72°C for 15 s). Quality control
amplification was confirmed by testing the human RNAse P gene.
This optimized PCR assay was compared to a commercial RT‐PCR
that amplifies SARS‐CoV‐2 E gene and S gene and includes an in-
ternal amplification control (Real Star® SARS‐CoV‐2 RT‐PCR Kit
1.0.; altona Diagnostics Argentina S.R.L.). Real time assays were
performed in a CFX 96 Deep Well™ Real Time System (BioRad).
A positive result was considered when the human RNAse gene
or the internal amplification control were positive and the cycle
threshold (Ct) value was less than 40. Analytical sensitivity was de-
termined with a quantified SARS‐CoV‐2 positive material (altona
Diagnostic, Argentina S.R.L.). Patient demographics were presented
using descriptive statistics.
Any patient with at least one positive test for SARS‐CoV‐2 was
considered true positive. Sensitivity, agreement, and Cohen's kappa
coefficient were calculated. Ct values and matched positive and
discrepant samples were compared by a Wilcoxon signed rank sum
test (GraphPad Prism 5.00).
3 | RESULTS
A total of 174 patients with signs or symptoms consistent with
COVID‐19 were enrolled. Clinical and demographic characteristics of
these patients are described in Table 1. The median age in the po-
pulation was 38 years old (interquartile range [IQR], 31–50) and
59.8% were females. The majority of patients (95%) had symptoms of
upper tract respiratory infection and 36% had fever. The median
time from the onset of symptoms to sample collection was 2 days
(IQR, 1–4). Nine patients (5.2%) required hospitalization and one of
them was admitted in the intensive care unit. Among SARS‐CoV‐2
RT‐PCR positive patients, the most common symptoms were fever
(36%), cough (46%), and odynophagia (49%).
A total of 348 samples (174 NPS and 174 saliva) were tested for
SARS‐CoV‐2 by RT‐PCR assays. Of 174 patients with symptoms,
63 (36%) were SARS‐CoV‐2 RT‐PCR positive in NPS by the opti-
mized home‐brew PCR assay. Of these 63 positive patients, 61 (98%)
were also positive in saliva and one additional patient was positive
only in saliva. The median Ct values in NPS versus saliva were 18.88
(IQR, 15.60–23.58; range, 11.97–38.10) versus 26.10 (IQR,
22.75–30.06; range, 13.78–39.22), respectively (p < .0001; Figure 1).
The median Ct value in saliva for RNAse P was 22.1 (IQR, 21.2–23.2;
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range, 19–28.1). Kappa Cohen's coefficient agreement between NPS
and saliva was 0.96 (95% confidence interval [CI], 0.92–0.99).
Discordant results between NPS and saliva occurred in 3/174
(1.7%) patients showing Ct values higher than 28. Specifically, E gene
Ct values in these three patients were 28.92 versus 41.00, 29.48
versus 41.00, and 44.00 versus 31.80, in NPS versus saliva, respec-
tively. This last patient SARS‐CoV‐2 RT‐PCR positive in saliva but
negative in NPS developed pneumonia (CT scan image compatible
with COVID‐19) requiring hospitalization. Workup on this patient for
additional respiratory pathogens including other respiratory viruses
by PCR and bacteria cultures in blood and respiratory samples were
negative. The other two patients who were SARS‐CoV‐2 RT‐PCR
positive in NPS but negative in saliva had provided a low volume of
saliva (<500 µl).
The comparison of the optimized home brew RT‐PCR and the
commercial assay showed different analytical and clinical sensitiv-
ities. The limit of detection of the optimized home brew RT‐PCR
assay and the commercial assay for SARS‐CoV‐2 was 1 copy/µl and
10 copies/µl, respectively. Of 62 patients with positive saliva by the
optimized home brew RT‐PCR, 54 (87%) were positive by the
TABLE 1 Baseline characteristics in
patients presenting to the emergency















Female 104 (59.8) 39 (60.9) 33 (60.0) 6 (66.7) 65 (59.1)
Male 70 (40.2) 25 (39.1) 22 (40.0) 3 (33.3) 45 (40.9)
Age (in years)
Median (IQR) 38 (31–50) 38 (31–50.5) 35 (30–46.3) 55 (41–67) 38.5 (31–48.5)
Mean (range) 41.1 (17–88) 41.8 (21–88) 39.3 (21–78) 56.2 (35–88) 40.7 (17–81)
Clinical syndrome, n (%)
URTI 165 (94.8) 55 (85.9) 55 (100) 0 110 (100)
Pneumonia 9 (5.2) 9 (14.1) 0 9 (100) 0
Abbreviations: COVID‐19, coronavirus disease 2019; IQR, interquartile range; NPS, nasopharyngeal
swabs; PCR, polymerase chain reaction; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus
2; URTI, upper respiratory tract infection.
a61 patients were positive in NPS and saliva; one patient was positive only in saliva; two patients were
positive only in NPS.
F IGURE 1 SARS‐CoV‐2 Ct in saliva and
nasopharyngeal swabs (NPS). (A) Ct median
from positive nasopharyngeal swabs (n = 63)
and saliva samples (n = 62) were compared
(p < .0001). (B) Patients matched positive and
discrepant samples (n = 64) represented by
the connecting lines were compared by a
Wilcoxon rank sum test (p < .0001).
SARS‐CoV‐2, severe acute respiratory
syndrome coronavirus 2
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commercial RT‐PCR. Agreement of both RT‐PCR assays was 94.6%
(kappa 0.9, 95% CI, 0.83–0.97). Saliva samples that were positive
with the optimized home brew RT‐PCR but negative with the com-
mercial kit had Ct values higher than 28 (mean Ct value 31.82; range,
28.93–39.22). Of 63 patients with positive NPS by the optimized
home brew RT‐PCR, 60 (95%) were positive by the commercial
RT‐PCR. All 3 discordant patients had a Ct value higher than 35.
4 | DISCUSSION
Nasopharyngeal swabbing has become a standard diagnostic test for
detection of SARS‐CoV‐2. However, NPS requires an invasive sam-
pling and further exposes healthcare workers to the pandemic virus.
Saliva is a noninvasive sample which can be easily obtained for viral
diagnosis.4 In this study, a high sensitivity (98%) and agreement
(kappa 0.96) in saliva samples compared to NPS was demonstrated
when using an optimized home brew PCR even in saliva samples with
a lower viral load. In addition, saliva was able to detect SARS‐CoV‐2
in one patient with negative NPS who developed pneumonia
requiring hospitalization. High detection rate in saliva has been
previously demonstrated in symptomatic and asymptomatic adults
suggesting that it can be used as a suitable specimen for detection of
SARS‐CoV‐2.6–8 In fact, such viral detection may be related to the
high expression of ACE2 receptors on the salivary glands and
tongue.9
In contrast, some studies have shown a lower sensitivity in saliva
compared with NPS.10 Saliva collection and/or processing as well as
sensitivity of the PCR assay may play a role in such lower perfor-
mances.10,11 In fact, the need of optimizing saliva collection and
processing has been previously suggested.12 In this study, saliva
collection without any transport media or any nucleic acid stabili-
zation proved to be adequate to achieve a high detection rate and
sensitivity. Furthermore, optimization of the in‐house RT‐PCR assay
increased the limit of detection compared with previous reports and
to the commercial assay also evaluated in this study.5 As viral loads
in saliva can be lower than in NPS, optimized and sensitive assays are
recommended. Discrepant results between both PCR assays were
observed in saliva samples when Ct values were higher than 28 and
occurred in NPS when Ct values were higher than 35. These results
underscore the importance of highly sensitive assays for accurate
diagnosis.
One limitation of this study is that patients were relatively young
and with mild symptoms. Saliva production may be diminished in
older and/or less collaborative patients. Therefore, the performance
of this test in other populations (e.g., older and sicker) will be further
investigated.
In conclusion, our study demonstrates that testing self‐collected
saliva can be as sensitive as the NPS for diagnosing COVID‐19
among ambulatory patients. Saliva collection and processing is
important to achieve adequate diagnosis. The use of pure saliva
without transport media or stabilizators showed no RNA degrada-
tion. This noninvasive sample is easy to collect, requires less
consumables, and avoids discomfort to patients. In addition, self‐
collection of saliva can diminish exposure to SARS‐CoV‐2 in health-
care personnel. Further studies are needed to evaluate the role of
saliva testing in other populations and settings.
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